Triple attack on pancreatic cancer: heat, chemo, and immunotherapy join forces
NCT ID NCT06831136
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This phase II trial tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Participants first receive standard chemotherapy, then an endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) to heat and destroy tumor tissue, followed by the immunotherapy drug pembrolizumab. The goal is to see if this combination can shrink tumors and improve outcomes. The study enrolls 24 adults with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (immunotherapy) and endoscopic ultrasound-guided radiofrequency ablation
What this could lead to
If it works, this combination could shrink tumors and improve survival for people with advanced pancreatic cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (24 participants) testing a new combination. It may not work better than standard treatments, and side effects from the procedures and immunotherapy could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.